RETROPHIN, INC. (NASDAQ:RTRX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
Retrophin, Inc. ExhibitEX-1.1 2 d620797dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 $240,…To view the full exhibit click here
About RETROPHIN, INC. (NASDAQ:RTRX)
Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.